Table 1.
Clinicopathologic data of TCGA cohort and GEO cohort.
| Variables | TCGA cohort | GSE39582 cohort | GSE17538 cohort |
|---|---|---|---|
| Age | 67.01 ± 12.77 | 66.95 ± 13.17 | 64.73 ± 13.43 |
| Gender | |||
| Male | 205 (53.2%) | 322 (55.0%) | 122 (52.6%) |
| Female | 180 (46.8%) | 263 (45.0%) | 110 (47.4%) |
| Grade | |||
| G1 | — | — | 17 (7.3%) |
| G2 | — | — | 166 (71.6%) |
| G3 | — | — | 30 (12.9%) |
| G4 | — | — | 0 (0%) |
| Unknown | — | — | 19 (8.2%) |
| Stage | |||
| I | 66 (17.1%) | 28 (17.1%) | 28 (12.1%) |
| II | 151 (39.2%) | 72 (17.1%) | 72 (31.0%) |
| III | 103 (26.8%) | 76 (17.1%) | 76 (32.8%) |
| IV | 54 (14.0%) | 56 (17.1%) | 56 (24.1%) |
| Unknown | 11 (2.9%) | 0 (0%) | 0 (0%) |
| T stage | |||
| T0 | 0 (0%) | 1 (0.2%) | — |
| Tis | 1 (0.3%) | 3 (0.5%) | — |
| T1 | 9 (2.3%) | 12 (2.0%) | — |
| T2 | 68 (17.7%) | 49 (8.4%) | — |
| T3 | 263 (68.3%) | 379 (64.8%) | — |
| T4 | 44 (11.4%) | 119 (20.3%) | — |
| Unknown | 0 (0%) | 22 (3.8%) | — |
| N stage | |||
| N0 | 231 (60.0%) | 314 (53.7%) | — |
| N1 | 88 (22.9%) | 137 (23.4%) | — |
| N2 | 66 (17.1%) | 100 (17.1%) | — |
| N3 | 0 (0%) | 6 (1.0%) | — |
| Unknown | 0 (0%) | 28 (4.8%) | — |
| M stage | |||
| M0 | 286 (74.3%) | 499 (85.3%) | — |
| M1 | 54 (14.0%) | 61 (10.4%) | — |
| Unknown | 45 (11.7%) | 25 (4.3%) | — |
| Tumor location | |||
| Distal | — | 351 (60.0%) | — |
| Proximal | — | 232 (39.7%) | — |
| Unknown | — | 2 (0.3%) | — |
| Chemotherapy adjuvant | |||
| Yes | — | 240 (41.0%) | — |
| No | — | 326 (55.7%) | — |
| Unknown | — | 19 (3.3%) | — |
| Survival | |||
| Yes | 79 (20.5%) | 194 (33.2%) | 93 (40.1%) |
| No | 306 (79.5%) | 385 (65.8%) | 139 (59.9%) |
| Unknown | 0 (0%) | 6 (1.0%) | 0 (0%) |